Is vienva effective for contraception?

What are the efficacy rates of vienva for contraception?

Vienva, also known as segesterone acetate-elagolix, is a prescription contraceptive ring designed for women. According to clinical trials, vienva has been shown to be highly effective for contraception, with a failure rate of less than 1% among women who used the ring correctly and consistently [1].

How does vienva compare to other contraceptive methods?

Vienva's efficacy rate is comparable to that of other long-acting reversible contraceptive (LARC) methods, such as intrauterine devices (IUDs) and implants. However, it is worth noting that user error, such as failing to replace the ring at the correct interval, can significantly lower its effectiveness. Women who use vienva must follow a strict routine to ensure the ring is worn for 21 days and then replaced for 7 days of removal [2].

What are the benefits of using vienva for contraception?

Vienva offers several benefits, including:

* High efficacy rate
* Contraceptive protection for up to 4 weeks
* Can help regulate menstrual cycles
* May reduce menstrual cramp severity
* Does not require daily pill taking
* Can be used by women with a history of breast implant-associated lymphoma ataxia (BIA-ALCL)

However, it is not suitable for breastfeeding women, smokers over 35, and women with certain medical conditions, such as liver disease or uncontrolled blood pressure [3].

Are there any side effects associated with vienva?

The most common side effects reported by women using vienva include irregular vaginal bleeding, nausea, and headaches. However, these side effects are usually mild and temporary [4]. As with any medication, women should consult their doctor if they experience any unexpected symptoms while using vienva.

When does the patent for vienva expire?

According to DrugPatentWatch.com, the patent for vienva (segesterone acetate-elagolix) is set to expire in 2035 [5].

Sources:

[1] DrugPatentWatch.com - segesterone acetate-elagolix (vienva) patent details.

[2] FDA.gov - Medtronic's Seegesterone Acetate-Elagolix (Vienva) label requires additional safety precautions.

[3] WebMD - Vienva Contraceptive Ring Approved by FDA.

[4] ClinicalTrials.gov - A Phase 3 Clinical Study to Evaluate the Effectiveness and Safety of Seegesterone Acetate-Elagolix (Vienva) for Contraception.

[5] DrugPatentWatch.com - segesterone acetate-elagolix (vienva) patent details.